COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance-Reference-Cited by-同舟云学术

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance

Published:2023-11 Issue:Supplement_2 Volume:78 Page:ii37-ii42
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Bou-Antoun Sabine¹^ORCID,Rokadiya Sakib²,Ashiru-Oredope Diane¹^ORCID,Demirjian Alicia¹³⁴,Sherwood Emma⁵,Ellaby Nicholas²,Gerver Sarah¹,Grossi Carlota⁶,Harman Katie⁷,Hartman Hassan²,Lochen Alessandra⁸^ORCID,Ragonnet-Cronin Manon²⁹¹⁰,Squire Hanna¹,Sutton J Mark¹¹¹²,Thelwall Simon⁷,Tree Julia¹¹,Bahar Mohammad W¹³,Stuart David I¹³¹⁴,Brown Colin S¹,Chand Meera²,Hopkins Susan¹

Affiliation:

1. Healthcare-Associated Infection (HCAI), Fungal, Antimicrobial Resistance (AMR), Antimicrobial Use (AMU) & Sepsis Division, United Kingdom Health Security Agency (UKHSA) , London , UK

2. Genomics Public Health Analysis (GPHA), United Kingdom Health Security Agency (UKHSA) , London , UK

3. Department of Paediatric Infectious Diseases & Immunology, Evelina London Children's Hospital , London , UK

4. Faculty of Life Sciences & Medicine, King’s College London , London , UK

5. Clinical and Emerging Infections (CEI), United Kingdom Health Security Agency (UKHSA) , London , UK

6. COVID-19 Rapid Evidence Service Public Health Advice, Guidance and Expertise (PHAGE), UK Health Security Agency , London NW9 5EQ , UK

7. COVID-19 Vaccines and Applied Epidemiology Division, UK Health Security Agency , London NW9 5EQ , UK

8. Tuberculosis (TB), Acute Respiratory, Zoonoses, Emerging and Travel infections Division, UK Health Security Agency , London NW9 5EQ , UK

9. MRC Centre for Global Infectious Disease Analysis, Imperial College London , London , UK

10. Department of Ecology and Evolution, University of Chicago , Chicago, IL , USA

11. Research and Evaluation, UK Health Security Agency, Porton Down , Salisbury SP4 0JG , UK

12. Institute of Pharmaceutical Sciences, King’s College London , London , UK

13. Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics , Oxford , UK

14. Diamond Light Source Ltd, Harwell Science & Innovation Campus , Didcot , UK

Abstract

Abstract The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.

Funder

UKRI MRC

National Institute for Health Research

Health Protection Research Unit

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

https://academic.oup.com/jac/article-pdf/78/Supplement_2/ii37/53710268/dkad314.pdf

Reference39 articles.

1. Antibiotic resistance: calling time on the ‘silent pandemic’;Mendelson;JAC Antimicrob Resist,2022

2. Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use;Rockett;N Engl J Med,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons identified for a future pandemic;Journal of Antimicrobial Chemotherapy;2023-11